Download PDF
Endoskopie heute 2013; 26(2): 161-165
DOI: 10.1055/s-0033-1335864
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Vorsorge des kolorektalen Karzinoms (KRK), unter besonderer Berücksichtigung der Lobbyarbeit zur Verbesserung von Information und Motivation Vorsorgeberechtigter

Wo stehen wir im Jahre 2013?Prevention of the Colorectal Carcinoma (CRC), with a Special Focus on the Significance of Outreach Work in Informing and Motivating Target GroupWhere are we in 2013?
D. Schilling
Further Information

Publication History

Publication Date:
16 July 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Teilnahmerate an den gesetzlich möglichen Vorsorgemaßnahmen für das kolorektale Karzinom (KRK) liegt mit 2 % pro Jahr untere der Rate, wie sie eigentlich von den Initiatoren erwartet wurde. Diese Daten zeigen, wie wichtig Lobbyarbeit ist, um eine breite Öffentlichkeit über die Möglichkeiten der KRK-Prävention zu informieren. Die Stiftung Lebensblicke hat in diesem Sinne viel auf den Weg gebracht. Sie begleitet wissenschaftliche Untersuchungen, ist aber auch in der politischen Arbeit aktiv. Erreicht wurde dadurch, dass die bisher opportunistische Prävention zu einem Einladungsverfahren umgewandelt wird. Im zukünftigen Fokus stehen jetzt die Implementierung des immunologischen Stuhltests in der Vorsorge und die risikoadaptierte Vorsorge.

Abstract

At 2 percent, the attendance rate of advised (?) preventative initiatives for the colectoral carcinoma is well below that expected by the initiators. These data show how important lobbying is in informing the general public about the possibilities of CRC prevention. The Foundation “Lebensblicke” has done a lot in this field supporting scientific projects as well as informing policy developments. As a result, previous selective prevention will now be replaced by preventative examinations prompted by invitation. Main foci for future perspectives will be the implementation of immunological stool tests as well as risk adapted prevention.

Schlüsselwörter

Prävention - kolorektales Karzinom

Key words

Prevention - colorectal cancer
 

  • Literatur

  • 1 Damian U, Schilling D, Riemann JF. Screening auf kolorektale Karzinome. Was ist gesichert – was wird empfohlen?. Internist Prax 2013; 53: 83-90
    PubMedGoogle Scholar
  • 2 Diamond SJ, Enestvedt BK, Jiang Z et al. Adenoma detection rate increases with each decade of life after 50 years of age. Gastroint Endosc 2011; 74: 135-140
    CrossrefPubMedGoogle Scholar
  • 3 Yuhara H, Yuhara H, Steinmaus C et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. J Gastroenterol 2011; 106: 1911-1921
    PubMedGoogle Scholar
  • 4 Anderson JC, Moezardalan K, Messina CR et al. Smoking and the association of advanced colorectal neoplasia in an asymptomatic average risk population: analysis of exposure and anatomical location in men and women. Dig Dis Sci 2011; 56: 3616-3623
    CrossrefPubMedGoogle Scholar
  • 5 Winawer SJ, Zauber AG, Ho MN et al. Reduction of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981
    PubMedGoogle Scholar
  • 6 Schmiegel W et al. S3 Leitlinie Kolorektales Karzinom. Z Gastroenterol 2008; 46: 1-73
    PubMedGoogle Scholar
  • 7 Tenckhoff B. KBV plädiert für gezielte Ausweitung. Deutsches Ärzteblatt 2013; 110 (15) A-703/B-617/C-617
    PubMedGoogle Scholar
  • 8 Pox C, Altenhofen L, Brenner H et al. Efficacy of a nationwide Screening Colonoscopy program for Colorectal cancer. Gastroenterology 2012; 142: 1460-1467
    CrossrefPubMedGoogle Scholar
  • 9 RKI Krebs in Deutschland 2007/2008 online auf der RKI Homepage.
    PubMedGoogle Scholar
  • 10 Rembacken B, Hassan C, Riemann JF et al. Quality in screening colonoscopy Position statement of the European society of Gastrointestinal Endoscopy (ESGE). Endoscopy 2012; 44: 957-968
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Webendörfer S, Messerer P, Eberle F et al. Precautions for intestinal cancer in the workplace. An initiative for secondary prevention in the BASF joint-stock company. Dtsch Med Wochenschr 2004; 129 (06) 239-243
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Schneider M, Häck HJ. Screening for colorectal cancer: a cost benefit analysis on a health prevention programme at the Boehringer Ingelheim Company. Dtsch Med Wochenschr 2011; 136 (20) 1047-1052
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Riemann JF, Maar C, Betzler M et al. Early detection of colonic cancer in the National Cancer Program – present status and recommendations. Z Gastroenterol 2011; 49 (10) 1428-1431
    PubMedGoogle Scholar
  • 14 Brenner H, Hoffmeister M, Arndt V et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102 (02) 89-95
    CrossrefPubMedGoogle Scholar
  • 15 Brenner H, Haug U, Arndt V et al. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 2010; 138 (03) 870-876
    CrossrefPubMedGoogle Scholar
  • 16 Hoffmeister M, Schmitz S, Karmrodt E et al. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clin Gastroenterol Hepatol 2010; 8 (10) 870-876 
    CrossrefPubMedGoogle Scholar
  • 17 Brenner H, Altenhofen L, Stock C et al. Natural history of colorectal adenomas: Birth cohort analysis among 3.6 million participants of screening colonoscopy. Cancer Epidemiol Biomarkers Prev 2013 Apr 30. [Epub ahead of print]
    PubMedGoogle Scholar
  • 18 Jorgensen OD, Kronborg O, Fenger C. A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50: 29-32
    CrossrefPubMedGoogle Scholar
  • 19 Kewenter J, Brevinge H, Engarås B et al. Results of screening, rescreening and follow-up in a prospective randomized study for detection of colorectal cancer by fecal-occult-blood testing. Scand J Gastroenterol 1994; 29: 468-473
    CrossrefPubMedGoogle Scholar
  • 20 Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for faecal occult blood. N Engl J Med 1993; 328: 1365-1371
    CrossrefPubMedGoogle Scholar
  • 21 Van Rossum LG et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90
    CrossrefPubMedGoogle Scholar
  • 22 von Karsa L, Patnick J, Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition – Executive summary. Endoscopy 2012; 44 (Suppl 3): SE 1 – 8. Epub 2012, Sep 25
    PubMedGoogle Scholar
  • 23 Quintero E, Castells A, Bujanda L et al. And the COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366 (08) 697-706
    CrossrefPubMedGoogle Scholar
  • 24 Knaebel HP, Kienle P. Patients at risk of familal colorectal cancer. Br Med J Med 2005; 331: 1033-1034
    PubMedGoogle Scholar
  • 25 Blanco GD, Cretella M, Paoluzi OA et al. Adenoma, advanced adenoma and colorectal cancer prevalence in asymptomatic 40 to 49-year-olds with a first-degree family history of colorectal cancer. Colorectal Dis 2013; Apr 30. [Epub ahead of print] DOI: 10.1111codi12263.
    PubMedGoogle Scholar
  • 26 Menges M, Fischinger J, Gärtner B et al. Screening colonoscopy in 40 to 50-year-old first degree relatives of patients with colorectal cancer is efficient: a controlled multicenter study. Int J Colorectal Dis 2006; 21: 301-307
    CrossrefPubMedGoogle Scholar
  • 27 Ait OuakrimD, Lockett T, Boussioutas A et al. Screening participation predictors for people at familial risk of colorectal cancer: a systematic review. Am J Prev Med 2013; 44 (05) 496-506
    CrossrefPubMedGoogle Scholar